| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
INO5042 is classified as a drug derivative with anti-inflammatory activity. Its mechanism involves modulation of endothelial and neutrophil behavior, reducing cell adhesion and slow rolling. The compound targets inflammatory processes by altering the velocity of endothelial cells and neutrophils, shifting speeds from 3-5 to 7-11 micrometers per second.
|
|---|---|
| ln Vitro |
When INO5042 was given to endothelial cells, a quick shift in velocity was detected (from 3-5 μm/sec to 7-11 μm/sec). The same outcomes were visible when neutrophils were subjected to INO5042 alone or combined with endothelial cells, and the quantity of stickers and rollers was likewise reduced [1].
In vitro, INO5042 demonstrates anti-inflammatory activity by modulating endothelial and neutrophil behavior. When added to endothelial cells, a shift of velocities is observed towards fast speeds (from 3-5 to 7-11 microm/sec). Similar results are seen when neutrophils are treated with INO5042 alone or in combination with endothelial cells, with reduced adhesion and rolling. Detailed IC₅0 values are not extensively documented. |
| ln Vivo |
In vivo activity data for INO5042 are not extensively documented. As an anti-inflammatory agent that modulates endothelial and neutrophil behavior, the compound is expected to show efficacy in inflammatory disease models. Further in vivo studies in appropriate animal models would be needed to fully characterize its pharmacokinetic and efficacy profile.
|
| Enzyme Assay |
The in vitro assay for INO5042 involves treating endothelial cells or neutrophils with the compound and measuring cell velocity using time-lapse microscopy or flow-based adhesion assays. Cells are incubated with varying concentrations of INO5042, and changes in velocity (from 3-5 to 7-11 microm/sec) are quantified. Adhesion and slow rolling are assessed under flow conditions to evaluate the compound's anti-inflammatory effects.
|
| Cell Assay |
For in vitro cell-based assays, endothelial cells or neutrophils are cultured and treated with INO5042 at various concentrations. Cell velocity is measured using live-cell imaging or microfluidic flow chambers. Adhesion assays are performed under physiological flow conditions to assess the compound's ability to reduce cell adhesion and rolling. Experiments are typically performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
In vivo animal studies for INO5042 would typically involve mouse models of inflammation (such as LPS-induced or carrageenan-induced inflammation models). The compound is administered orally or intraperitoneally at various doses. Inflammatory markers are measured in blood or tissue samples, and leukocyte adhesion and rolling are assessed using intravital microscopy. Efficacy is evaluated by reduction in inflammatory parameters.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of INO5042 are not extensively documented. The compound has molecular weight 281.29 and molecular formula C1₅H₇NO3S. It is soluble in DMSO and typically formulated for in vitro studies. Purity is reported as 99.92%. The compound is classified as a reference compound. Further detailed PK parameters (half-life, Cmax, AUC, bioavailability) would require dedicated studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for INO5042 are not well characterized in the public domain. As a research chemical, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications. Comprehensive toxicity profiling including genotoxicity, organ toxicity, and maximum tolerated dose studies would be required for therapeutic development.
|
| References |
[1]. Renard M, et al. Induced changes of leukocyte slow rolling in an in flow pharmacological model of adhesion to endothelial cells. Biorheology. 2003;40(1-3):173-8.
[2]. Fosse C, et, al. Parameters and mechanistic studies on the oxidative ring cleavage of synthetic heterocyclic naphthoquinones by Streptomyces strains. Appl Microbiol Biotechnol. 2004 Sep;65(4):446-56. |
| Additional Infomation |
INO5042 (CAS# 14782-19-5) is a thiazole-fused 1,4-naphthoquinone compound with anti-inflammatory activity. It alters endothelial and neutrophil behavior, reducing adhesion and slow rolling. The compound has molecular formula C1₅H₇NO3S and molecular weight 281.29. It is used as a reference compound in inflammation research and is not approved for clinical use.
|
| Molecular Formula |
C15H7NO3S
|
|---|---|
| Molecular Weight |
281.285982370377
|
| Exact Mass |
281.014
|
| CAS # |
14782-19-5
|
| PubChem CID |
10446437
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
504.1±42.0 °C at 760 mmHg
|
| Flash Point |
258.7±27.9 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.684
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
441
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C2SC(C3=CC=CO3)=N1)C4=C(C=CC=C4)C2=O
|
| InChi Key |
VJKZUTFFMNSTTD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H7NO3S/c17-12-8-4-1-2-5-9(8)13(18)14-11(12)16-15(20-14)10-6-3-7-19-10/h1-7H
|
| Chemical Name |
2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2 mg/mL (~7.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5550 mL | 17.7752 mL | 35.5505 mL | |
| 5 mM | 0.7110 mL | 3.5550 mL | 7.1101 mL | |
| 10 mM | 0.3555 mL | 1.7775 mL | 3.5550 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
